��������

Dr. Sue Dillon, Ph.D. is co-founder, President, and CEO of Aro Biotherapeutics, a start-up biotech focused on developing and commercializing Centyrins, a proprietary protein drug platform with the potential to revolutionize the delivery of diverse drug classes, including nucleic acids and genetic therapies.

Sue has 30 years in executive leadership roles at pharmaceutical and biotech companies. She retired from her role as Global Therapeutic Area Head for Immunology at Janssen/J&J in 2017. During her 16+ year tenure at J&J, Sue led global Immunology R&D and achieved numerous regulatory approvals for innovative antibody products for autoimmune diseases including REMICADE®, SIMPONI®, STELARA® and TREMFYA® that delivered combined end-user sales in excess of $10B. During her tenure, Sue built a robust Immunology development portfolio through internal discovery, and external licensing, and championed research into the emerging areas of the microbiome and immune repertoire profiling. Multi-disciplinary teams under Sue’s leadership were twice recognized with the Prix Galien Award for PROMACTA® and STELARA®, each first in class medicine.

Sue received her Ph.D. in Immunology from Thomas Jefferson University in Philadelphia and completed a postdoctoral fellowship in Immunology at Duke University. Sue was named by FierceBiotech as one of the “Top Women in Biotech”. Currently, Sue is CEO of Aro Biotherapeutics and serves on the Board of Directors of the Wistar Institute.